<DOC>
	<DOCNO>NCT00727727</DOCNO>
	<brief_summary>The objective Post Marketing Surveillance Study investigate use non-ergot dopamine agonist piribedil ( trade name : CLARIUM ) mono- combination therapy patient Morbus Parkinson . Neurologists private practice Germany document safety course disease/change parkinsonian symptom stabilisation , change dopamine agonist treatment routine condition . Piribedil prescribe accord marketing authorisation .</brief_summary>
	<brief_title>SEDPARK2 : Post Marketing Surveillance Observe Safety Efficacy Piribedil Parkinson 's Disease ( PIR-002/K )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Piribedil</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>Male female patient 18 year old . Indication : Morbus Parkinson . Treatment piribedil first time . Monotherapy piribedil . Combination therapy LDopa ( begin secondary combination antiparkinsonian drug ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Piribedil ( trade name : Clarium )</keyword>
	<keyword>non-ergot dopamine agonist</keyword>
	<keyword>Morbus Parkinson</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Post Marketing Surveillance</keyword>
</DOC>